NASDAQ$IBRX
ImmunityBio Inc · Q3 2024 earnings
Q3 2024 earnings · · Investor relations
Briefing
Reported financial results for the third-quarter ended September 30, 2024.
ImmunityBio reported a net product revenue of approximately $6.0 million during the three months ended September 30, 2024, surpassing net product revenue of $1.0 million in the prior quarter and analyst estimates. The company's cash and marketable securities position was $130.4 million as of September 30, 2024.
- ANKTIVA received a J-code (HCPCS Level II Code) in October 2024, effective January 1, 2025.
- ANKTIVA is now widely accessible to patients through commercial and government insurance programs, securing coverage for over 200 million medical lives.
- Net product revenue reached approximately $6.0 million during the three months ended September 30, 2024, exceeding the previous quarter and analyst estimates.
- The company has extended the shelf life of ANKTIVA from two years to three years, with over 125,000 doses available.
Headline financials
Revenue & EPS history
ImmunityBio · Revenue · Quarterly
$6.11M
Forward guidance
The company anticipates an EU submission this quarter.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2024
-0.5%
Avg return
Earnings day
-0.4%
Avg return
5 days after
-1.9%
Avg return
30 days after
49%
21 / 43 earnings
Positive
+40.4%
Q3 2018
Best reaction
-63.3%
Q1 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -7.5% | -3.2% | -17.5% | |
| Q4 2025 | +13.2% | +12.4% | -7.2% | |
| Q3 2025 | +3.4% | +3.8% | +10.1% | |
| Q1 2025 | +6.4% | +20.3% | +35.2% | |
| Q4 2024 | +6.0% | +5.3% | +4.2% | |
| Q3 2024 | -11.4% | -17.6% | -44.2% | |
| Q2 2024 | -17.2% | -11.7% | -20.3% | |
| Q1 2024 | +2.5% | +6.1% | -23.0% | |
| Q4 2023 | +14.5% | +16.1% | -6.1% | |
| Q3 2023 | -9.3% | +5.8% | +0.0% | |
| Q2 2023 | -9.7% | -1.1% | -29.2% | |
| Q1 2023 | -63.3% | -46.8% | -54.3% | |
| Q4 2022 | -16.8% | -27.9% | -25.4% | |
| Q3 2022 | +7.4% | +26.3% | +26.3% | |
| Q2 2022 | -3.3% | +0.7% | +0.4% | |
| Q1 2022 | -19.3% | +5.1% | +16.6% | |
| Q4 2021 | -4.6% | -9.8% | -11.3% | |
| Q3 2021 | -8.7% | -10.9% | -24.9% | |
| Q2 2021 | -0.1% | -10.8% | -12.2% | |
| Q4 2020 | +14.7% | -4.2% | -12.3% | |
| Q1 2021 | +14.7% | +10.4% | +5.0% | |
| Q3 2020 | -3.5% | -0.7% | +26.6% | |
| Q2 2020 | +7.2% | -11.4% | -39.0% | |
| Q1 2020 | +17.5% | +3.0% | +46.8% | |
| Q4 2019 | +16.4% | +5.4% | +21.8% | |
| Q3 2019 | +2.8% | +3.7% | +38.9% | |
| Q2 2019 | +8.3% | +13.3% | +4.2% | |
| Q1 2019 | -7.3% | -12.2% | -15.4% | |
| Q4 2018 | +1.7% | +2.5% | +16.8% | |
| Q3 2018 | +40.4% | -10.9% | -41.9% | |
| Q2 2018 | -7.8% | -1.3% | +2.2% | |
| Q1 2018 | +0.5% | +4.6% | -4.3% | |
| Q4 2017 | -6.5% | -10.7% | -17.8% | |
| Q3 2017 | -5.7% | -2.8% | +17.3% | |
| Q2 2017 | +5.4% | -0.5% | +5.8% | |
| Q1 2017 | +5.5% | +35.8% | +49.5% | |
| Q4 2016 | -2.0% | -0.3% | -3.7% | |
| Q3 2016 | +2.2% | +1.2% | -12.8% | |
| Q2 2016 | -2.2% | -3.1% | +20.6% | |
| Q1 2016 | +1.8% | — | — | |
| Q4 2015 | -3.3% | — | — | |
| Q3 2015 | -3.5% | — | — | |
| Q2 2015 | -1.4% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro